Dr. Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research Biomedical Research Centre Clinician Scientist at The Institute of Cancer Research, London, UK.
Dr. Yap gained his BSc degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford. Dr. Yap undertook a Clinical Fellowship in the Phase I Drug Development Unit at the Royal Marsden Hospital, before completing a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics at The Institute of Cancer Research under a Cancer Research UK Fellowship. Dr. Yap completed his specialist training in medical oncology at the Royal Marsden Hospital and was awarded a National Institute for Health Research (NIHR) Academic Clinical Lectureship in Medical Oncology. He was subsequently appointed as Consultant Medical Oncologist and NIHR Biomedical Research Centre Clinician Scientist.
Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the development of novel immunotherapeutics and the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR and PARP inhibitors.